DE10333835A1 - 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung - Google Patents

6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung Download PDF

Info

Publication number
DE10333835A1
DE10333835A1 DE10333835A DE10333835A DE10333835A1 DE 10333835 A1 DE10333835 A1 DE 10333835A1 DE 10333835 A DE10333835 A DE 10333835A DE 10333835 A DE10333835 A DE 10333835A DE 10333835 A1 DE10333835 A1 DE 10333835A1
Authority
DE
Germany
Prior art keywords
dimethylaminomethyl
diol
weight
cyclohexane
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10333835A
Other languages
German (de)
English (en)
Inventor
Johannes Bartholomaeus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE10333835A priority Critical patent/DE10333835A1/de
Priority to JP2006520768A priority patent/JP2006528604A/ja
Priority to EP04741158A priority patent/EP1648420A2/de
Priority to PCT/EP2004/008081 priority patent/WO2005009329A2/de
Priority to CA002533330A priority patent/CA2533330A1/en
Publication of DE10333835A1 publication Critical patent/DE10333835A1/de
Priority to US11/334,344 priority patent/US20060121113A1/en
Priority to US12/757,455 priority patent/US20100196473A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE10333835A 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung Ceased DE10333835A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE10333835A DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
JP2006520768A JP2006528604A (ja) 2003-07-24 2004-07-20 ６−ジメチルアミノメチル−１−（３−メトキシ−フェニル）−シクロヘキサン−１，３−ジオールを含む、有効物質徐放性医薬
EP04741158A EP1648420A2 (de) 2003-07-24 2004-07-20 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verz gerter wirkstofffreisetzun g
PCT/EP2004/008081 WO2005009329A2 (de) 2003-07-24 2004-07-20 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
CA002533330A CA2533330A1 (en) 2003-07-24 2004-07-20 Pharmaceutical preparation containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US11/334,344 US20060121113A1 (en) 2003-07-24 2006-01-19 Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US12/757,455 US20100196473A1 (en) 2003-07-24 2010-04-09 Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10333835A DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
DE10333835A1 true DE10333835A1 (de) 2005-03-10

Family

ID=34088810

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10333835A Ceased DE10333835A1 (de) 2003-07-24 2003-07-24 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Country Status (6)

Country Link
US (2) US20060121113A1 (https=)
EP (1) EP1648420A2 (https=)
JP (1) JP2006528604A (https=)
CA (1) CA2533330A1 (https=)
DE (1) DE10333835A1 (https=)
WO (1) WO2005009329A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110060053A1 (en) 2002-09-09 2011-03-10 Gruenenthal Gmbh Crystalline Modifications of 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol
DE102005009217A1 (de) * 2005-02-25 2006-08-31 Grünenthal GmbH Phosphatsalze der 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexanverbindungen
MX2007010192A (es) 2005-02-25 2007-09-07 Gruenenthal Chemie Formas cristalinas del clorhidrato de (1rs, 3rs, 6rs)-6-dimetilaminometil-1-(3-metoxi-fenil) ciclohexano-1, 3-diol.
EP1695957A1 (en) * 2005-02-25 2006-08-30 Grünenthal GmbH Crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DE102007022790A1 (de) 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol zur Schmerzbehandlung bei Arthrose
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
EP2085081A1 (de) 2008-02-04 2009-08-05 Grünenthal GmbH 3-(2-Dimethylaminomethyl-cyclohexyl)-phenol gegen polyneuropathischen Schmerz
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
DE102008042603A1 (de) * 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implantat sowie Verfahren zur Herstellung einer degradationshemmenden Schicht auf einer Körperoberfläche eines Implantats
WO2011008298A2 (en) * 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
US20110053914A1 (en) 2009-08-28 2011-03-03 Gruenenthal Gmbh Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
WO2012000667A1 (en) 2010-06-30 2012-01-05 Grünenthal GmbH Axomadol or metabolite thereof for use in the treatment of irritable bowel syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4315525A1 (de) * 1993-05-10 1994-11-17 Euro Celtique Sa Pharmazeutische Zusammensetzung
EP0753506B1 (de) * 1995-07-11 1999-08-18 Grünenthal GmbH 6-Dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE10059413A1 (de) * 2000-11-30 2002-06-20 Gruenenthal Gmbh Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4315525A1 (de) * 1993-05-10 1994-11-17 Euro Celtique Sa Pharmazeutische Zusammensetzung
EP0753506B1 (de) * 1995-07-11 1999-08-18 Grünenthal GmbH 6-Dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe

Also Published As

Publication number Publication date
WO2005009329A3 (de) 2005-06-30
JP2006528604A (ja) 2006-12-21
EP1648420A2 (de) 2006-04-26
US20060121113A1 (en) 2006-06-08
CA2533330A1 (en) 2005-02-03
US20100196473A1 (en) 2010-08-05
WO2005009329A2 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
DE10333835A1 (de) 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
AU2016416435B2 (en) Liquid cleansing compositions with an antibacterial system and method of manufacturing thereof
MXPA04003742A (es) Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.
EP3484469B1 (en) Compositions and methods of potentiating antimicrobials
Kehr et al. Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®
CA2832854C (en) Method of inhibiting harmful microorganisms and barrier-forming composition therefor
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
AU4047600A (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
EP2263667A3 (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
CH650926A5 (de) Antiparkinson-mittel.
EP0935461B1 (de) Adamantanaminenderivate zur bekämpfung von viren der familie bornaviridae
DE4315525B4 (de) Pharmazeutische Zusammensetzung
WO2014107572A1 (en) Body surface treatment composition and method
US10426761B2 (en) Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
DE69713586T2 (de) Dosisformen und deren verwendungen
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática
WO2006107593A3 (en) Matrix-based pulse release pharmaceutical formulation
CZ285681B6 (cs) Použití selegilinu pro výrobu farmacetického prostředku k ošetřování epileptických onemocnění a farmaceutický prostředek, který selegilin obsahuje
DE102015115876A1 (de) Substanz zur Prophylaxe und Behandlung von Infektionen durch Influenzaviren
DE60108650T2 (de) 1-amino-alkylcyclohexanederivate als trypanocide mittel
DK181405B1 (en) Gel for Intranasal Application, its Provision and Use
US20240041852A1 (en) Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
MY134311A (en) Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
Bafghi et al. Antileishmanial Activity of Carum Copticum Essential Oil Against Leishmania Major [MRHO/IR/75/ER]: An In Vitro Study

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final

Effective date: 20121005